Scientists have made a breakthrough in treating pancreatic cancer by targeting a previously "undruggable" target, which has led to a significant increase in survival time. The target in question is KRAS, a key factor in pancreatic cancer, and a new inhibitor therapy has shown promising results. The development has been hailed as a major breakthrough, with experts and patients welcoming the new treatment approach.